WO2012112792A3 - Multicomponent compositions and their uses - Google Patents

Multicomponent compositions and their uses Download PDF

Info

Publication number
WO2012112792A3
WO2012112792A3 PCT/US2012/025479 US2012025479W WO2012112792A3 WO 2012112792 A3 WO2012112792 A3 WO 2012112792A3 US 2012025479 W US2012025479 W US 2012025479W WO 2012112792 A3 WO2012112792 A3 WO 2012112792A3
Authority
WO
WIPO (PCT)
Prior art keywords
multicomponent
methods
multicomponent composition
component
compositions
Prior art date
Application number
PCT/US2012/025479
Other languages
French (fr)
Other versions
WO2012112792A2 (en
Inventor
David H. Coy
Lichun Sun
Original Assignee
The Administrators Of The Tulane Educational Fund
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Administrators Of The Tulane Educational Fund filed Critical The Administrators Of The Tulane Educational Fund
Priority to CA2862798A priority Critical patent/CA2862798C/en
Priority to CN201280009550.9A priority patent/CN103501823B/en
Priority to US13/985,051 priority patent/US9358272B2/en
Publication of WO2012112792A2 publication Critical patent/WO2012112792A2/en
Publication of WO2012112792A3 publication Critical patent/WO2012112792A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Multicomponent compositions and methods of use thereof are disclosed herein. Some embodiments of the present invention include multicomponent compositions comprising a first component and a second component, where the first component comprises a notch influencing molecule and the second component comprises a GPCR targeted molecule. Kits comprising the multicomponent composition are also disclosed. Methods for providing the multicomponent composition to one or more cells are additionally provided. Further embodiments include methods of using the multicomponent composition such as, for example, methods of administering the multicomponent composition and method of treating organisms (such as mammals) using the multicomponent composition.
PCT/US2012/025479 2011-02-17 2012-02-16 Multicomponent compositions and their uses WO2012112792A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA2862798A CA2862798C (en) 2011-02-17 2012-02-16 Multicomponent compositions and their uses
CN201280009550.9A CN103501823B (en) 2011-02-17 2012-02-16 Multi-component combination and their purposes
US13/985,051 US9358272B2 (en) 2011-02-17 2012-02-16 Multicomponent compositions and their uses

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161463482P 2011-02-17 2011-02-17
US61/463,482 2011-02-17
US201161558227P 2011-11-10 2011-11-10
US61/558,227 2011-11-10

Publications (2)

Publication Number Publication Date
WO2012112792A2 WO2012112792A2 (en) 2012-08-23
WO2012112792A3 true WO2012112792A3 (en) 2013-02-21

Family

ID=46673182

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/025479 WO2012112792A2 (en) 2011-02-17 2012-02-16 Multicomponent compositions and their uses

Country Status (4)

Country Link
US (1) US9358272B2 (en)
CN (2) CN108514638A (en)
CA (1) CA2862798C (en)
WO (1) WO2012112792A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011162558A2 (en) * 2010-06-24 2011-12-29 (주)지노믹트리 Recombinant vector for suppressing proliferation of human papillomavirus cell including adenylate cyclase activating polypeptide 1 (pituitary) gene and pharmaceutical composition for treating human papillomavirus
CN108514638A (en) 2011-02-17 2018-09-11 杜兰教育基金委员会 Multi-component combination and their purposes
TW201726746A (en) 2012-11-07 2017-08-01 輝瑞股份有限公司 Anti-Notch3 antibodies and antibody-drug conjugates
EP3433259B1 (en) 2016-03-24 2021-06-30 The Administrators of The Tulane Educational Fund Conjugates of tacrolimus, their compositions, and their uses
US20210386877A1 (en) * 2019-01-10 2021-12-16 Andarix Pharmaceuticals, Inc. Radiotherapeutic combination therapy for the treatment of cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002010215A1 (en) * 2000-07-31 2002-02-07 Dabur Research Foundation Somatostatin analogs for the treatment of cancer
WO2003042246A2 (en) * 2001-11-14 2003-05-22 Lorantis Limited Inhibitors of the notch signalling pathway for use in the treatment of cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2461099A1 (en) * 2001-09-21 2003-04-10 The Administrators Of The Tulane Educational Fund Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof
KR101003622B1 (en) 2002-03-01 2010-12-24 더 어드미니스트레이터 오브 더 튜레인 에듀케이셔널 펀드 Conjugates of therapeutic or cytotoxic agents and biologically active peptides
CN101856348A (en) 2003-08-29 2010-10-13 斯隆-凯特林癌症研究所 The therapeutic alliance method for cancer
EP1954284A4 (en) 2005-11-04 2010-01-06 Merck & Co Inc Method of treating cancers with saha and pemetrexed
CA2655362A1 (en) 2006-06-13 2007-12-21 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
CN108514638A (en) 2011-02-17 2018-09-11 杜兰教育基金委员会 Multi-component combination and their purposes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002010215A1 (en) * 2000-07-31 2002-02-07 Dabur Research Foundation Somatostatin analogs for the treatment of cancer
WO2003042246A2 (en) * 2001-11-14 2003-05-22 Lorantis Limited Inhibitors of the notch signalling pathway for use in the treatment of cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FRANKO-TOBIN, L.G. ET AL.: "Notchl-mediated tumor suppression in cervical cancer with the involvement of SST signaling and its application in enhanced SSTR-targeted therapeutics", ONCOLOGIST, vol. 17, no. 2, 30 January 2012 (2012-01-30), pages 220 - 232 *
KASPERLIK-ZALUSKA, A.A. ET AL.: "'ACTH responses to somatostatin, valproic acid and dexamethasone in Nelson's syndrome'", NEUROENDOCRINOL. LETT., vol. 26, no. 6, 2005, pages 709 - 712 *

Also Published As

Publication number Publication date
US9358272B2 (en) 2016-06-07
CN103501823A (en) 2014-01-08
CA2862798A1 (en) 2012-08-23
CN108514638A (en) 2018-09-11
US20140045752A1 (en) 2014-02-13
CN103501823B (en) 2018-05-04
CA2862798C (en) 2021-04-06
WO2012112792A2 (en) 2012-08-23

Similar Documents

Publication Publication Date Title
WO2013067349A9 (en) Novel chemistry used in biosensors
BR112014015909A8 (en) composition
UA114611C2 (en) PESTICIDIC COMPOSITIONS AND METHODS RELATING TO THEM
WO2010034032A3 (en) Methods for preparing purified polypeptide compositions
WO2010008847A3 (en) Pi3k/m tor inhibitors
EA201391602A1 (en) CONTROLLED EMISSION OF IMMUNODPRESSANTS FROM SYNTHETIC NANO MEDIA
MY150542A (en) Cmet inhibitors
WO2012109035A3 (en) Stable bio-oil
EA201400311A1 (en) АМИНОЗАМЕЩЕННЫЕ ИМИДАЗОПИРИДАЗИНЫ
WO2010027975A8 (en) Boron-containing small molecules
BR112018069876A2 (en) cosmetic composition, method for photostabilization of resveratrol, polydatin, or a mixture thereof with baicalin and
WO2009047644A3 (en) Method of treating vitamin d insufficiency and deficiency
WO2008115890A3 (en) Mapk/erk kinase inhibitors
WO2009145996A3 (en) Amide derivatives as positive allosteric modulators and methods of use thereof
WO2010032011A3 (en) Anti-fungal therapy
UA111357C2 (en) Epoxyeicosatrienoic acid analogs, composition based thereon, use in the treatment of diseases and method of reducing hypertension and nephrotoxicity
WO2014053401A3 (en) Method of improving plant health
WO2012112792A3 (en) Multicomponent compositions and their uses
WO2010017368A3 (en) Methods and compositions for treating anxiety
NZ701463A (en) Anti-phytopathogenic composition
WO2009090394A3 (en) Composition containing capsicum for treating a skin disorder
BR112013027965A2 (en) "coating composition, substrate and method for coating a substrate"
WO2009129497A3 (en) Methods and compositions for treating age-related macular degeneration
WO2014097318A3 (en) Agents for eliminating tumour-initiating cells
AU2012248013B2 (en) Intermediate for synthesizing caspofungin and preparation method therefor

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 13985051

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 12747148

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2862798

Country of ref document: CA